ASCO: American Society of Clinical Oncology

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option.

By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.

Remote therapeutic monitoring (RTM) with ePROs powered by AI cuts hospitalizations and boosts therapy time—now a key oncology leader promotes guideliens and reimbursement to make it standard of care.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

OPTIMA trial data show genomic testing helps many patients with high‑risk breast cancer skip chemotherapy safely and start endocrine therapy sooner.

Canopy remote therapeutic monitoring with ePROs cuts hospitalizations and extends time to discontinuation in metastatic cancer, saving millions.

Chemotherapy decisions for young women with HR+ breast cancer and low recurrence scores reveal testing disparities that health systems must address.

An AI-driven review of oncology trials reveals that diversity progress over 30 years is largely an illusion driven by Asian enrollment growth.

Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.

From cardiovascular risk to missed toxicity grading, Igor Puzanov, MD, MSCI, outlines what is failing in checkpoint inhibitor toxicity management.

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.

Data presented at ASCO support wider use of prophylactic therapy to prevent cytokine release syndrome as efforts expand to promote bispecifics in treatment of multiple myeloma.

Data confirm the use of daratumumab, bortezomib, lenalidomide, and dexamethasone as the standard of care in newly diagnosed multiple myeloma.

ADC targeting both PSMA and STEAP1 with a topoisomerase payload showed a 15-month PFS signal in heavily pretreated prostate cancer—far above historical chemotherapy benchmarks.

Updated SUNMO phase 3 data show Mosun-Pola cuts progression risk by 62% vs R-GemOx, with a 75% ORR and 61% CR rate in second-line R/R LBCL at 28-month follow-up.

An entirely new approach to treating one of the most intractable cancers could turn it into a chronic disease.

Adding the anti-CD19 monoclonal antibody and lenalidomide to the classic combination drove superior PFS, with a positive trend in OS. Higher rates of adverse events offset the positive survival results in an area of great unmet need.

Early data for LINKER-AL2 show linvoseltamab drives rapid and deep responses following relapse after frontline treatment for AL amyloidosis, which has no approved therapies.

ARACOG trial data highlight cognitive effects of ARPIs in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, notes Alicia Morgans, MD, MPH.

Updated toxicity criteria improve immunotherapy toxicity management in melanoma, spotlighting rapid action for rare cardiotoxicity, says Igor Puzanov, MD, MSCI, FACP.

According to the ROADS trial, GammaTile cesium-131 brachytherapy boosts local control and survival in brain cancer treatment, matching SRT safety while avoiding radiation delays.

Early palliative care integration in oncology boosts symptom alleviation and quality of life, but access, workforce shortages, and institutional barriers slow referrals.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Mezigdomide, a powerful CELMoD, doubles PFS in relapsed multiple myeloma, offering hope when IMiDs stop working.

ASCO 2026 spotlights practice-changing cancer data: PROTEUS in prostate cancer, RAS(ON) inhibitor daraxonrasib, new bispecifics, and GLP-1 signals.

Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.

Continuing his interview about these results, CEPHEUS lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, highlights the minimal residual disease negativity findings.

Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.

The COCOON trial reveals that prophylactic treatment reduces dermatological adverse events in NSCLC patients, enhancing their quality of life during amivantamab therapy.